Medication AdherenceNCT01603329
Increasing Medication Adherence Through Physician Incentives and Messaging
A study testing Increasing Medication Adherence through Physician Incentives and Messaging in people with Medication Adherence, run by National Bureau of Economic Research, Inc. at 1 site in United States.
Trial summary
The goal of this project is to increase patient adherence to medication using communications and incentives for physicians. The investigators are partnering with a health insurance company, Humana Inc, to design and implement an incentives program for physicians whose patients increase their medication adherence for… Read more about this study
- Who is it for?
- Ages 65 years and older
- Conditions the study is for
- Medication Adherence
- What is being tested?
- Increasing Medication Adherence through Physician Incentives and Messaging
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 734 participants
- Where
- 1 siteUnited States
- Study dates
- Jun 2012to Mar 2014
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 65 years and older
- All sexes
- No healthy volunteers
- Older adult
Who may be able to join
- Physician in the Humana network
- Treats Humana Medicare Advantage Members
- Has Humana Medicare Advantage members who are taking at least one of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, and/or cholesterol (statins) medication, and who are less than 80% adherent.
Who cannot join
- Practices with more than 10 physicians
Trial locations and contacts
1 site in 1 country.
About this study
The goal of this project is to increase patient adherence to medication using communications and incentives for physicians. The investigators are partnering with a health insurance company, Humana Inc, to design and implement an incentives program for physicians whose patients increase their medication adherence for oral diabetes medication, hypertension (ACEI or ARB) medication, and/or cholesterol (statins) medication. The investigators will use behavioral economics to explore the best way to communicate the incentives to the physicians.
Read the detailed description
Traditional economics would suggest that the best way to maximize adherence would be to give physicians financial incentives to improve adherence to all relevant drugs, and that communications to physicians should emphasize all of the relevant drugs. Behavioral economics suggests theory suggests that if you emphasize everything, then you are effectively emphasizing nothing. Behavioral econonmics would suggest to maximize adherence one should give physicians financial incentives for improving adherence for a small number of relevant drugs, and communications to physicians should emphasize a small number of the relevant drugs. This allows physicians to focus their energy and reduces the probability that they will give up because they're overwhelmed, or in other words, avoid the phenomenon called metric fatigue.
Humana has already implemented an incentives program for physicians, and the investigators will work with them to design a program that just focuses on medication adherence. Physicians targeted for this pilot could also be enrolled in another Humana incentives program, but this incentives program will act independently of the other.
There are two treatment dimensions the investigators will test via random assignment at the practice level:
- Physicians given financial incentives for improving patient medication adherence for all of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, and cholesterol (statins) medication vs. one of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, or cholesterol (statins) medication.
- Physicians given communication emphasizing the importance of improving adherence to all of the previous medication classes vs. one one of the previous medication classes.
In a previous study to increase uptake of colonoscopies among employees at a partner firm, the investigators found that using a post it note to catch the attention of the employee statistically significantly increased colonoscopy uptake over a control group. The investigators will also employ an eye catching method in the proposed pilot. When physicians are sent a communication regarding the opportunity to receive an incentive as part of our pilot, they will also receive a single patient sheet for each patient who has less than 80% adherence. They will be encouraged to include the patient sheet in their chart as a reminder to discuss medication adherence with their patient the next time they see them. For half of our arms, the investigators will make the patient sheets a bright, non-white, color, in order to futher draw the physicians' attention to that specific paper in their chart.
Our experimental arms will be:
- Comprehensive incentives + comprehensive communication
- Comprehensive incentives + comprehensive communication + printed on bright non-white paper
- Focused incentives + focused communication (one for all three drug classes)
- Focused incentives + focused communication + printed on bright non-white paper (one for all three drug classes)
- Comprehensive communiation
- Comprehensive communication + printed on bright non-white paper
- Control arm: no communication + no incentives
The investigators hypothesize that physicians who receive focused incentives and focused communications will have more patients with increased medication adherence than physicians who receive comprehensive incentives and comprehensive communications. The investigators also hypothsize that physicians who receive patient sheets using bright, non-white paper will have more patients with increased medication adherence than physicians who receive plain white patient sheets.
- Conditions
- Medication Adherence
- Being tested
- Increasing Medication Adherence through Physician Incentives and Messaging
- Keywords
- medication adherence, diabetes, hypertension, cholesterol, statins
- Medical subject headings
- Medication Adherence, Diabetes Mellitus, Hypertension
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Increasing Medication Adherence through Physician Incentives and MessagingOther
Also called Adherence
There are two treatments:
- Physicians given financial incentives for improving patient medication adherence for all of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, and cholesterol (statins) medication vs. one of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, or cholesterol (statins) medication.
- Physicians given communication emphasizing the importance of improving adherence to all of the previous medication classes vs. one one of the previous medication classes.
When physicians are sent a communication regarding the opportunity to receive an incentive as part of our pilot, they will also receive a single patient sheet for each patient who has less than 80% adherence. For half of the arms, the investigators will make the patient sheets a bright, non-white, color, in order to further draw the physicians' attention to that specific paper in their chart.
| Study group | Role | What they receive |
|---|---|---|
| Comprehensive incentives + comprehensive communication | Experimental | Physicians are given financial incentives for improving patient medication adherence for all of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, and cholesterol (statins) medication. Receives: Other: Increasing Medication Adherence through Physician Incentives and Messaging |
| Comp incentives + comp communication + non-white paper | Experimental | Physicians are given financial incentives for improving patient medication adherence for all of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, and cholesterol (statins) medication, and their patient reports are printed on non-white bright colored paper. Receives: Other: Increasing Medication Adherence through Physician Incentives and Messaging |
| Focused incentives + focused com for oral diabetes medication | Experimental | Physicians are given financial incentives for improving patient medication adherence for oral diabetes medication. Receives: Other: Increasing Medication Adherence through Physician Incentives and Messaging |
| Foc incentives + foc comm for Diabetes + non-white paper | Experimental | Physicians given financial incentives for improving patient medication adherence for oral diabetes medication and patient reports are printed on bright non-white paper. Receives: Other: Increasing Medication Adherence through Physician Incentives and Messaging |
| Focused incentives + focused comm for hypertension meds | Experimental | Physicians are given financial incentives for improving patient medication adherence for hypertension (ACEI or ARB) medication. Receives: Other: Increasing Medication Adherence through Physician Incentives and Messaging |
| Foc incentives + comm for hypertension meds + non-white paper | Experimental | Physicians are given financial incentives for improving patient medication adherence for hypertension (ACEI or ARB) medication with patient reports on non-white paper. Receives: Other: Increasing Medication Adherence through Physician Incentives and Messaging |
| Focused incentives + focused comm for cholesterol meds | Experimental | Physicians given financial incentives for improving patient medication adherence for cholesterol (statins) medication. Receives: Other: Increasing Medication Adherence through Physician Incentives and Messaging |
| Foc incentives +comm for cholesterol meds + non-white paper | Experimental | Physicians given financial incentives for improving patient medication adherence for cholesterol (statins) medication and patient reports are printed on non-white paper. Receives: Other: Increasing Medication Adherence through Physician Incentives and Messaging |
| Comprehensive communiation | Experimental | Physicians are given communication emphasizing the importance of improving adherence to all of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, and cholesterol (statins) medication. Receives: Other: Increasing Medication Adherence through Physician Incentives and Messaging |
| Comprehensive communication + non-white paper | Experimental | Physicians are given communication emphasizing the importance of improving adherence to all of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, and cholesterol (statins) medication and patient reports are printed on non-white paper. Receives: Other: Increasing Medication Adherence through Physician Incentives and Messaging |
| Control Arm | Experimental | Physicians and their patient adherence is tracked, but they receive no intervention. Receives: Other: Increasing Medication Adherence through Physician Incentives and Messaging |
What is being measured
The primary outcome is the main question the study is designed to answer.
Medication Adherence
The investigators will see how the treatment arms affect the targeted physicians' patients medication adherence for oral diabetes medication, hypertension (ACEI or ARB) medication, and cholesterol (statins) medication.
Measured: Up to two years
Secondary outcomes (2)
Demographic Controls for Physicians
The investigators will see if our targeted physicians' demographic controls affect their patients' medication adherence rates before and after treatment.
Measured: Up to two years
Demographic Controls for Patients
The investigators will see how demographic controls for patients affect our targeted physicians' patients' medication adherence.
Measured: Up to 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 May 2012 (estimated)
- Study startJun 2012
- Primary completionFeb 2014
- Study completionMar 2014
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Medication AdherenceStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 734 participants (actual)
Sponsor and investigators
- Lead sponsor
- National Bureau of Economic Research, Inc.
- Sponsor type
- University, hospital or other
- Collaborators
- Humana Inc.
- Responsible party
- Sponsor
- Investigators
- David I Laibson, Ph.D., Principal investigator, National Bureau of Economic Research, Harvard University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01603329
- Sponsor's protocol ID
- 007
- Status last verified
- Oct 2015
- First submitted
- 16 May 2012
- Last updated
- 23 Oct 2015
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 Oct 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Increasing Medication Adherence Through Physician Incentives and Messaging
- ClinicalTrials.gov ID
- NCT01603329
- Acronym / sponsor ID
- 007
- Conditions
- Medication Adherence
- Keywords
- medication adherence, diabetes, hypertension, cholesterol, statins
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 734 participants (actual)
- Lead sponsor
- National Bureau of Economic Research, Inc.University, hospital or other
- Collaborators
- Humana Inc.
- Study start
- Jun 2012
- Primary completion
- Feb 2014 (actual)
- Study completion
- Mar 2014 (actual)
- First posted
- 22 May 2012 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this project is to increase patient adherence to medication using communications and incentives for physicians. The investigators are partnering with a health insurance company, Humana Inc, to design and implement an incentives program for physicians whose patients increase their medication adherence for oral diabetes medication, hypertension (ACEI or ARB) medication, and/or cholesterol (statins) medication. The investigators will use behavioral economics to explore the best way to communicate the incentives to the physicians.
Detailed description
Traditional economics would suggest that the best way to maximize adherence would be to give physicians financial incentives to improve adherence to all relevant drugs, and that communications to physicians should emphasize all of the relevant drugs. Behavioral economics suggests theory suggests that if you emphasize everything, then you are effectively emphasizing nothing. Behavioral econonmics would suggest to maximize adherence one should give physicians financial incentives for improving adherence for a small number of relevant drugs, and communications to physicians should emphasize a small number of the relevant drugs. This allows physicians to focus their energy and reduces the probability that they will give up because they're overwhelmed, or in other words, avoid the phenomenon called metric fatigue.
Humana has already implemented an incentives program for physicians, and the investigators will work with them to design a program that just focuses on medication adherence. Physicians targeted for this pilot could also be enrolled in another Humana incentives program, but this incentives program will act independently of the other.
There are two treatment dimensions the investigators will test via random assignment at the practice level:
- Physicians given financial incentives for improving patient medication adherence for all of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, and cholesterol (statins) medication vs. one of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, or cholesterol (statins) medication.
- Physicians given communication emphasizing the importance of improving adherence to all of the previous medication classes vs. one one of the previous medication classes.
In a previous study to increase uptake of colonoscopies among employees at a partner firm, the investigators found that using a post it note to catch the attention of the employee statistically significantly increased colonoscopy uptake over a control group. The investigators will also employ an eye catching method in the proposed pilot. When physicians are sent a communication regarding the opportunity to receive an incentive as part of our pilot, they will also receive a single patient sheet for each patient who has less than 80% adherence. They will be encouraged to include the patient sheet in their chart as a reminder to discuss medication adherence with their patient the next time they see them. For half of our arms, the investigators will make the patient sheets a bright, non-white, color, in order to futher draw the physicians' attention to that specific paper in their chart.
Our experimental arms will be:
- Comprehensive incentives + comprehensive communication
- Comprehensive incentives + comprehensive communication + printed on bright non-white paper
- Focused incentives + focused communication (one for all three drug classes)
- Focused incentives + focused communication + printed on bright non-white paper (one for all three drug classes)
- Comprehensive communiation
- Comprehensive communication + printed on bright non-white paper
- Control arm: no communication + no incentives
The investigators hypothesize that physicians who receive focused incentives and focused communications will have more patients with increased medication adherence than physicians who receive comprehensive incentives and comprehensive communications. The investigators also hypothsize that physicians who receive patient sheets using bright, non-white paper will have more patients with increased medication adherence than physicians who receive plain white patient sheets.
Study design
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 11
| Arm | Type | Receives |
|---|---|---|
| Comprehensive incentives + comprehensive communication | Experimental | Other: Increasing Medication Adherence through Physician Incentives and MessagingPhysicians are given financial incentives for improving patient medication adherence for all of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, and cholesterol (statins) medication. |
| Comp incentives + comp communication + non-white paper | Experimental | Other: Increasing Medication Adherence through Physician Incentives and MessagingPhysicians are given financial incentives for improving patient medication adherence for all of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, and cholesterol (statins) medication, and their patient reports are printed on non-white bright colored paper. |
| Focused incentives + focused com for oral diabetes medication | Experimental | Other: Increasing Medication Adherence through Physician Incentives and MessagingPhysicians are given financial incentives for improving patient medication adherence for oral diabetes medication. |
| Foc incentives + foc comm for Diabetes + non-white paper | Experimental | Other: Increasing Medication Adherence through Physician Incentives and MessagingPhysicians given financial incentives for improving patient medication adherence for oral diabetes medication and patient reports are printed on bright non-white paper. |
| Focused incentives + focused comm for hypertension meds | Experimental | Other: Increasing Medication Adherence through Physician Incentives and MessagingPhysicians are given financial incentives for improving patient medication adherence for hypertension (ACEI or ARB) medication. |
| Foc incentives + comm for hypertension meds + non-white paper | Experimental | Other: Increasing Medication Adherence through Physician Incentives and MessagingPhysicians are given financial incentives for improving patient medication adherence for hypertension (ACEI or ARB) medication with patient reports on non-white paper. |
| Focused incentives + focused comm for cholesterol meds | Experimental | Other: Increasing Medication Adherence through Physician Incentives and MessagingPhysicians given financial incentives for improving patient medication adherence for cholesterol (statins) medication. |
| Foc incentives +comm for cholesterol meds + non-white paper | Experimental | Other: Increasing Medication Adherence through Physician Incentives and MessagingPhysicians given financial incentives for improving patient medication adherence for cholesterol (statins) medication and patient reports are printed on non-white paper. |
| Comprehensive communiation | Experimental | Other: Increasing Medication Adherence through Physician Incentives and MessagingPhysicians are given communication emphasizing the importance of improving adherence to all of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, and cholesterol (statins) medication. |
| Comprehensive communication + non-white paper | Experimental | Other: Increasing Medication Adherence through Physician Incentives and MessagingPhysicians are given communication emphasizing the importance of improving adherence to all of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, and cholesterol (statins) medication and patient reports are printed on non-white paper. |
| Control Arm | Experimental | Other: Increasing Medication Adherence through Physician Incentives and MessagingPhysicians and their patient adherence is tracked, but they receive no intervention. |
Who may qualify
- Ages
- 65 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Older adult
Key inclusion criteria (3 listed)
- Physician in the Humana network
- Treats Humana Medicare Advantage Members
- Has Humana Medicare Advantage members who are taking at least one of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, and/or cholesterol (statins) medication, and who are less than 80% adherent.
Key exclusion criteria (1 listed)
- Practices with more than 10 physicians
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Increasing Medication Adherence through Physician Incentives and MessagingAlso: AdherenceThere are two treatments: 1. Physicians given financial incentives for improving patient medication adherence for all of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, and cholesterol (statins) medication vs. one of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, or cholesterol (statins) medication. 2. Physicians given communication emphasizing the importance of improving adherence to all of the previous medication classes vs. one one of the previous medication classes. When physicians are sent a communication regarding the opportunity to receive an incentive as part of our pilot, they will also receive a single patient sheet for each patient who has less than 80% adherence. For half of the arms, the investigators will make the patient sheets a bright, non-white, color, in order to further draw the physicians' attention to that specific paper in their chart. | Other | Comp incentives + comp communication + non-white paper, Comprehensive communiation, Comprehensive communication + non-white paper, Comprehensive incentives + comprehensive communication, Control Arm, Foc incentives + comm for hypertension meds + non-white paper, Foc incentives + foc comm for Diabetes + non-white paper, Foc incentives +comm for cholesterol meds + non-white paper, Focused incentives + focused com for oral diabetes medication, Focused incentives + focused comm for cholesterol meds, Focused incentives + focused comm for hypertension meds |
Primary outcome
Medication Adherence
Time frame: Up to two years
The investigators will see how the treatment arms affect the targeted physicians' patients medication adherence for oral diabetes medication, hypertension (ACEI or ARB) medication, and cholesterol (statins) medication.
2 secondary outcomes
Demographic Controls for Physicians
Time frame: Up to two years
Demographic Controls for Patients
Time frame: Up to 2 years
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Oct 2015.
Related trials for Medication Adherence
Recruiting
DiaFootCare to Promote Self-Care of Diabetic Foot Ulcers in Oman
Diabetic Foot Ulcer (DFU), Diabetes Mellitus
Enrolling by invitation
Symptom Monitoring Using Patient-Report to Improve Medication Use
Breast Cancer Early Stage Breast Cancer (Stage 1-3), Endocrine Therapy
Not yet recruiting
Team-Based Shared Decision-Making Program in Hypertension Control (Healthy Heart - BP Program)
Hypertension (HTN), Blood Pressure
Not yet recruiting
The AYA Oncology Self-care Movement
Acute Lymphobkastic Leukemia, Medication Adherence
Active, not recruiting
Leveraging Technology to Improve Medication Adherence in Youth With Kidney or Liver Transplant
Transplant;Failure,Kidney, Transplant; Failure, Liver
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
David I Laibson, Ph.D. principal investigator
National Bureau of Economic Research, Harvard University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Increasing Medication Adherence through Physician Incentives and Messaging in people with Medication Adherence, run by National Bureau of Economic Research, Inc. at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 23 Oct 2015. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Medication Adherence (time frame: Up to two years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Oct 2015.